Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EFPIA Urges Japan To Consider New Funding Models

Executive Summary

Amid intensifying official scrutiny of rising drug costs, the European industry federation EFPIA would like Japan to focus more on the measuring the actual benefits and health outcomes of new therapies, helped by new approaches and technology.

You may also be interested in...



Pricey New HCV, Cancer Drugs Push Up Japan’s Health Care Costs

Japan has reported big rises in drug costs covered by its national health insurance scheme, driven in large part by hepatitis C and cancer, adding weight to ongoing discussions of possible new cost containment measures.

EFPIA Highlights Europe ‘Lessons’ As Japan Ponders Policies

EFPIA remains cautious over moves in Japan towards a formal health technology assessment system and possible changes to the reimbursement pricing system, calling again for the maintenance of an environment conducive to pharma innovation and pointing to lessons from its experience in Europe.

Drug Industry Urges Caution Over Japan HTA Plans

Japan's Ministry of Health, Labour and Welfare has decided on a pilot health technology assessment (HTA) program to be initiated in 2016, which will be applied initially only to a limited number of existing approved drugs.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS119337

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel